Targeting a protein to treat acute myeloid leukaemia in children
Dr Karen Keeshan is researching to see if removing or blocking a specific protein involved in acute myeloid leukaemia can help make it easier to treat.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dr Karen Keeshan is researching to see if removing or blocking a specific protein involved in acute myeloid leukaemia can help make it easier to treat.
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Dr Samanta Mariani and her team want to understand more about the role immune cells play to help develop new ways to treat leukaemia in babies.
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Professor Shivaram Avula will identify markers in the brains of young people with brain tumours that will help predict the development of long-term side effects like learning and memory problems.
Dr Jonathan Fisher aims to create an 'off the shelf' version of immunotherapy to for hard-to-treat Ewing sarcoma.
Dr Olivier Pardo will investigate how osteosarcoma cells which escape into the bloodstream survive to spread elsewhere in the body.
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.